Aardvark Therapeutics expands Phase 3 HERO trial age eligibility to 7+ years for ARD-101 in PWS

Aardvark Therapeutics, Inc.

IRB approved amended protocol lowering minimum age from 10 to 7 years for Phase 3 HERO trial evaluating ARD-101.
Amended protocol submitted to FDA; enrollment on track for topline data in Q3 2026.
Trial targets 90 patients across US, Australia, Canada, UK, and South Korea.
Primary endpoint: change in HQ-CT score at 12 weeks; open-label extension offered to completers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.